U.S. markets open in 4 hours 37 minutes

Organogenesis Holdings Inc. (ORGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.74000.0000 (0.00%)
At close: 04:00PM EST
2.7000 -0.04 (-1.46%)
After hours: 04:08PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close2.7400
Bid0.0000 x 1800
Ask0.0000 x 1800
Day's Range2.7004 - 2.8000
52 Week Range2.2300 - 10.6600
Avg. Volume813,900
Market Cap358.707M
Beta (5Y Monthly)1.62
PE Ratio (TTM)6.37
EPS (TTM)0.4300
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
37% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ORGO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organogenesis Holdings Inc.
    ORGO: What does Argus have to say about ORGO?ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Motley Fool

    Organogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Call Transcript

    Good afternoon, ladies and gentlemen, and welcome to the third quarter 2022 earnings conference call for Organogenesis Holdings Inc. [Operator instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated Including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A risk factors of the company's most recent annual report and its subsequently files quarterly report.

  • GlobeNewswire

    Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

    CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared

  • Simply Wall St.

    Organogenesis Holdings (NASDAQ:ORGO) shareholders have endured a 72% loss from investing in the stock a year ago

    As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...